Bovilis BVD

1 x 10 ml

Suspension for injection

Active substance

Bovine viral diarrhea / pestivirus (BVDV1) (strain C-86) (attenuated)

ATC code

QI02AA01 Bovine viral diarrhea (BVD)

QI02AA Inactivated viral vaccines

QI02A Immunologicals for cattle

QI02 Immunologicals for bovidae

QI Immunologicals

Species

Cattle (cows and heifers).

Indications

For active immunisation of cows and heifers from eight months of age onwards to protect the foetus against transplacental infection with bovine viral diarrhoea virus.

Dose to be administered and administration route

Before using the vaccine allow it to reach ambient temperature (15 °C – 25 °C).

Shake well before use. Use sterile syringes and needles.

Intramuscular injection. 2 ml per animal.

All cattle can be vaccinated from an age of eight months onwards.

Foetal protection can be expected if the primary immunisation has been finalised 4 weeks before start of the gestation. Animals which are vaccinated later than 4 weeks before gestation or during the early gestation will not be protected against foetal infection.

Individual vaccination

Basic immunisation

Two vaccinations with an interval of 4 weeks. The second vaccination should be given not later than 4 weeks before the start of the gestation.

Revaccination

One vaccination 4 weeks before start of the next gestation.

Herd vaccination

Basic immunisation

Two vaccinations with an interval of 4 weeks. For use in cattle from eight months of age, all animals should be vaccinated.

Revaccination

One vaccination 6 months after basic vaccination with next revaccinations at an interval no greater than 12 months.

For revaccination, the vaccine may be used for reconstitution of Bovilis IBR Marker Live for use in cattle from 15 months of age (i.e. those that have previously been vaccinated separately with Bovilis BVD and Bovilis IBR Marker Live) and the following instructions should be used:

Bovilis IBR Marker Live		Bovilis BVD
5 doses	+	10 ml
10 doses	+	20 ml
25 doses	+	50 ml
50 doses	+	100 ml

A single dose (2 ml) of Bovilis BVD mixed with Bovilis IBR Marker Live is given intramuscularly.

Visual appearance after reconstitution of Bovilis IBR Marker Live in Bovilis BVD:

As specified for Bovilis BVD alone.

Adverse reactions

Cattle:

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Injection site swelling¹.

Pyrexia².

Hypersensitivity reaction, anaphylactic shock³.

¹ Observed for 14 days.

² Transient and mild.

³ In the event of anaphylactic type reactions appropriate treatment with antihistamine, corticosteroid or adrenaline is recommended.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.